Dr. Tompkins is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Zuckerberg San Francisco General Hospital and Trauma Center
1001 Potrero Ave, Ward 95
San Francisco, CA 94110Phone+1 628-206-3645
Summary
- Dr. David Tompkins is a psychiatrist in San Francisco, CA and is affiliated with multiple hospitals in the area, including Zuckerberg San Francisco General Hospital and Trauma Center and UCSF Medical Center. He received his medical degree from New York Medical College and has been in practice 13 years. He specializes in addiction, gay, lesbian, transgender focused, and pain medicine and is experienced in chronic pain, withdrawal, and hyperalgesia. He has more than 50 publications and over 500 citings.
Education & Training
- Johns Hopkins Bloomberg School of Public HealthMHS, Clinical Investigation, 2011 - 2014
- Johns Hopkins University School of MedicinePost-Doctoral Fellowship, 2008 - 2010
- Johns Hopkins UniversityChief Residency, Psychiatry, 2007 - 2008
- Johns Hopkins UniversityResidency, Psychiatry, 2004 - 2008
- New York Medical CollegeClass of 2004
- Emory UniversityBS, English / Biology, High Honors in Biology, 1995 - 1999
Certifications & Licensure
- CA State Medical License 2017 - 2025
- MD State Medical License 2006 - 2025
- American Board of Psychiatry and Neurology Psychiatry
- American Board of Preventive Medicine Addiction Medicine
- American Society of Addiction MedicineAddiction Medicine
Awards, Honors, & Recognition
- Young Investigator Travel Award American Pain Society, 2013
- NIDA Director's Travel Award recipient CPDD Annual Meeting, 2009
- Travel Award to College on Problems of Drug Dependence (CPDD) Johns Hopkins, 2006
- Join now to see all
Clinical Trials
- Study on the Development of Opioid Induced Hyperalgesia (OIH) After Exposure to Alfentanil Start of enrollment: 2009 Feb 01
- Medications Development for Drug Abuse Disorders Start of enrollment: 2010 Oct 01
Publications & Presentations
PubMed
- 135 citationsExtended-release injectable naltrexone for opioid use disorder: a systematic review.Brantley P. Jarvis, August F. Holtyn, Shrinidhi Subramaniam, D. Andrew Tompkins, Emmanuel A. Oga
Addiction. 2018-07-01 - 98 citationsIs diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies.Caiyun Liao, Dongyu Zhang, Chemtai Mungo, D. Andrew Tompkins, Amer M. Zeidan
Gynecologic Oncology. 2014-10-01 - 61 citationsSex differences in measures of central sensitization and pain sensitivity to experimental sleep disruption: implications for sex differences in chronic pain.Michael T. Smith, Bethany Remeniuk, Patrick H. Finan, Traci J. Speed, D. Andrew Tompkins
Sleep. 2019-02-01
Journal Articles
- Prefrontal Cortex Response to Drug Cues, Craving, and Current Depressive Symptoms Are Associated with Treatment Outcomes in Methadone-Maintained PatientsMichael S Kidorf, D Andrew Tompkins, Nature
- Sex Differences in Measures of Central Sensitization and Pain Sensitivity to Experimental Sleep Disruption: Implications for Sex Differences in Chronic PainTraci J Speed, D Andrew Tompkins, Patrick H Finan, Sleep
- Sleep duration mediates the relationship between ethnic differences and experimental pain perceptionMcCauley L, Bond K, Bounds S, Tripp M, Buenaver L, Tompkins D, Smith M, Haythornthwaite J, Campbell C, J Pain, 4/1/2013
- Join now to see all
Professional Memberships
- Member
- Member
- Member
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/david-tompkins
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: